RxDoctor Payments Data

Jack Chelebian, MD

Psychiatry · Corpus Christi, TXNPI 1295763399

Payments from drug & device makers

$8,775in general payments, 2019–2025

Across 74 payments — averaging $118.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Otsuka America Pharmaceutical, Inc.$6K
  • Alkermes, Inc.$487
  • Sunovion Pharmaceuticals Inc.$412
  • E.r. Squibb & Sons, L.L.C.$341
  • Lundbeck LLC$311
  • Teva Pharmaceuticals USA, Inc.$296
  • plus $640 from 8 others

What the payments were for

  • Speaking & faculty fees$4,70154%
  • Travel & lodging$1,24114%
  • Food & beverage$2,72131%
  • Education$1111%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,775 in reported general payments places this provider in the 85th percentile of 2,238 psychiatry providers in Texas.

See all psychiatry providers in Texas

Medicare billing

Part B allowed, 2024
$11,192
Medicare patients
39
Services billed
111

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
AustedoDeutetrabenazine83$849,189
Invega SustennaPaliperidone Palmitate125$387,074
Invega TrinzaPaliperidone Palmitate21$188,369
Abilify MaintenaAripiprazole41$123,395
FanaptIloperidone11$40,709
AristadaAripiprazole Lauroxil12$36,310
Aripiprazole223$9,800
Paliperidone ErPaliperidone55$8,660
Divalproex Sodium ErDivalproex Sodium164$6,820
Quetiapine Fumarate202$3,943
Olanzapine178$3,938
Lurasidone Hcl52$3,244
Trazodone Hcl276$3,203
Clozapine27$2,827
Gabapentin233$2,647

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Teva Pharmaceuticals USA, Inc.Austedo$296$849,18983 claims
Johnson & JohnsonInvega Sustenna, Invega Trinza$183$575,444146 claims
Otsuka America Pharmaceutical, Inc.Abilify Maintena$6,288$123,39541 claims
Vanda Pharmaceuticals Inc.Fanapt$103$40,70911 claims
Alkermes, Inc.Aristada$487$36,31012 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,238 psychiatry providers in Texas.

Other psychiatry in Corpus Christi

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →